Physician profile
Kai Mithoefer
NPI 1275504219
$64,105.35
in general payments reported to CMS, 2019-2025
14 companies · $2,155 in 2025
The $2,155 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,850 · 2021: $1,360 · 2022: $9,257 · 2023: $9,165 · 2024: $18K · 2025: $2,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,775 · Honoraria: $5,225 · Travel and Lodging: $1,263 · Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,350.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,775.00 |
| Honoraria | $5,225.00 |
| Travel and Lodging | $1,262.86 |
| Food and Beverage | $1,223.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $58,124.50 | 2019-2025 | Maci |
| Miach Orthopaedics, INC. | $3,830.36 | 2021-2024 | |
| Kairos Surgical INC | $990.22 | 2023 | |
| Arthrex, INC. | $442.48 | 2023 | |
| Abbott Laboratories | $256.22 | 2025 | Optis, Dragonfly Opstar |
| Smith+Nephew, INC. | $137.24 | 2023 | N/A |
| Ferring Pharmaceuticals INC. | $85.90 | 2022-2024 | Euflexxa |
| Pacira Therapeutics, INC. | $59.48 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $54.59 | 2024-2025 | |
| Biotissue Holdings INC. | $49.89 | 2024 | |
| Orthofix Medical, INC. | $23.56 | 2024 | Physio-Stim |
| Convatec INC. | $18.80 | 2024 | |
| Depuy Synthes Sales INC. | $16.33 | 2024 | Orthovisc, Monovisc |
| Biomerieux INC | $15.78 | 2023 | Filmarray 2.0 Instrument |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Mithoefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.